Global Neuralgia Treatment Market (2020 to 2027) – Size, Share & Trends Analysis Report – ResearchAndMarkets.com

Global Neuralgia Treatment Market (2020 to 2027) – Size, Share & Trends Analysis Report – ResearchAndMarkets.com




Global Neuralgia Treatment Market (2020 to 2027) – Size, Share & Trends Analysis Report – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Neuralgia Treatment Market Size, Share & Trends Analysis Report, By Treatment; By End-Use; By Region, and Segment Forecasts, 2020-2027” report has been added to ResearchAndMarkets.com’s offering.

The global neuralgia treatment market size is predicted to reach USD 2.83 billion by 2027, according to the study. The report gives a detailed insight into current market dynamics and provides analysis on future market growth.

The neuralgia treatment market is expected to witness significant growth owing to the increasing incidences of diabetes and trigeminal neuralgia. Furthermore, multiple sclerosis is also one of factors which can cause neuralgia. Multiple sclerosis decreases the body immunity owing to the neurodegenerative condition which affects the myelin sheath that can cause neuralgia. This is likely to drive market demand over the forecast period.

The potential drug candidates and the expected drug approval is expected to stimulate the global market, with high concentration of pharmaceutical companies engaged in the research & development of novel drugs for neuralgia treatment. For instance, U.S.-based drug manufacturer, Biogen Inc. is developing BIIB074 (Vixotrigine) for the treatment of trigeminal neuralgia and is currently in phase II.

Companies Mentioned

  • Allergan Plc
  • GlaxoSmithKline Plc.
  • Biogen Inc.
  • Abbott Laboratories
  • PixarBio Corporation
  • Merz Pharma GmbH
  • Trigemina Inc.
  • Pfizer Inc.
  • Novartis
  • Lupin

Key Topics Covered:

1. Introduction

2. Executive Summary

3. Research Methodology

4. Neuralgia Treatment Market Insights

4.1. Neuralgia Treatment – Industry snapshot

4.2. Neuralgia Treatment Market Dynamics

4.2.1. Drivers and Opportunities

4.2.1.1. High incidence rate of Neuralgia

4.2.1.2. Sports injuries causing neurodegenerative disorders

4.2.2. Restraints and Challenges

4.2.2.1. High cost of treatment

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers (Moderate)

4.3.2. Threats of New Entrants: (Low)

4.3.3. Bargaining Power of Buyers (Moderate)

4.3.4. Threat of Substitute (Moderate)

4.3.5. Rivalry among existing firms (High)

4.4. PESTLE Analysis

4.5. Neuralgia Treatment Market Industry trends

5. Neuralgia Treatment Market Assessment by Treatment

5.1. Key Findings

5.2. Introduction

5.3. Drug Based

5.4. Surgery

6. Global Neuralgia Treatment Market, by End Use

6.1. Key Findings

6.2. Introduction

6.2.1. Global Neuralgia Treatment Market, By End Use, 2016-2027 (USD Million)

6.3. Hospital & Clinics

6.3.1. Global Neuralgia Treatment Market, by Hospital & Clinics, By Region, 2016-2027 (USD Million)

6.4. Ambulatory Surgery Centers

6.4.1. Global Neuralgia Treatment Market, by Ambulatory Surgery Centers, by Region, 2016-2027 (USD Million)

6.5. Others

6.5.1. Global Neuralgia Treatment Market, by Others, by Region, 2016-2027 (USD Million)

7. Neuralgia Treatment Market Assessment by Geography

7.1. Key findings

7.2. Introduction

7.2.1. Neuralgia Treatment Market Assessment, By Geography, 2016-2027 (USD Million)

7.3. Neuralgia Treatment Market – North America

7.4. Neuralgia Treatment Market – Europe

7.5. Neuralgia Treatment Market – Asia-Pacific

7.6. Neuralgia Treatment Market – Middle East & Africa

7.7. Neuralgia Treatment Market – Latin America

8. Competitive Landscape

8.1. Expansion and Acquisition Analysis

8.1.1. Expansion

8.1.2. Acquisitions

8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

9.1. Allergan Plc

9.1.1. Company Overview

9.1.2. Financial Performance

9.1.3. Product Benchmarking

9.1.4. Recent Developments

9.2. Merz Pharma GmbH & Co.

9.3. Abbott Laboratories

9.4. Trigemina Inc.

9.5. Pfizer Inc.

9.6. Novartis

9.7. GlaxoSmithKline Plc.

9.8. Lupin

9.9. Cadila Healthcare Limited

9.10. Lundbeck Pharmaceuticals LLC

9.11. Biogen

For more information about this report visit https://www.researchandmarkets.com/r/vk9li

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900